Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
ADAP

Adaptimmune Therapeutics Plc

ADAP

0.47USD0.00 (0.00%)Market Closed
Watchlist

Market Summary

USD0.470.00
Market Closed
0.00%

ADAP Alerts

  • Losses in recent quarter

ADAP Stock Price

View Fullscreen

ADAP RSI Chart

ADAP Valuation

Market Cap

639.9M

Price/Earnings (Trailing)

-6.72

Price/Sales (Trailing)

9

EV/EBITDA

-6.49

Price/Free Cashflow

-4.87

ADAP Price/Sales (Trailing)

ADAP Profitability

EBT Margin

-124.81%

Return on Equity

-71.87%

Return on Assets

-26.54%

Free Cashflow Yield

-20.54%

ADAP Fundamentals

ADAP Revenue

Revenue (TTM)

71.1M

Revenue Y/Y

4.45%

Revenue Q/Q

42.67%

ADAP Earnings

Earnings (TTM)

-95.2M

Earnings Y/Y

-10.09%

Earnings Q/Q

-113.2%

Price Action

Last 7 days

11.6%

Last 30 days

-12.7%

Last 90 days

-40%

Trailing 12 Months

-78.2%

How does ADAP drawdown profile look like?

ADAP Financial Health

Current Ratio

3.44

ADAP Investor Care

Shares Dilution (1Y)

38.55%

Diluted EPS (TTM)

-0.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202371.2M70.8M71.1M0
20229.3M11.7M17.5M27.1M
20213.6M6.2M6.2M6.1M
20201.7M2.2M3.2M4.0M
201944.9M30.3M15.7M1.1M
201843.2M48.7M62.3M59.5M
201714.1M17.3M42.1M37.8M
201614.7M12.2M9.7M14.2M
20157.6M9.9M12.2M14.5M
20140825.0K3.1M5.3M

Latest Insider Trading transactions for ADAP

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 01, 2023
rawcliffe adrian
sold
-1,874
0.78
-2,403
chief executive officer
Aug 01, 2023
lunger john
sold
-2,803
0.9056
-3,096
chief patient supply officer
Jul 10, 2023
menzel garry e
sold
-43,447
0.9108
-47,702
-
Jun 27, 2023
rawcliffe adrian
sold
-2,146
0.92
-2,333
chief executive officer
Jun 01, 2023
menzel garry e
acquired
-
-
209,931
-
Jun 01, 2023
menzel garry e
acquired
-
-
401,293
-
Jan 31, 2023
piccina cintia
sold
-22,229
1.8696
-11,890
chief commercial officer
Jan 17, 2023
bertrand william c jr
sold
-8,249
1.858
-4,440
chief operating officer
Jan 17, 2023
rawcliffe adrian
sold
-18,685
1.858
-10,057
chief executive officer
Jan 17, 2023
lunger john
sold
-8,249
1.858
-4,440
chief patient supply officer

1–10 of 50

Which funds bought or sold ADAP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Nov 15, 2023
CAPTRUST FINANCIAL ADVISORS
unchanged
-
-3,179
17,101
-%
Nov 15, 2023
GSA CAPITAL PARTNERS LLP
sold off
-100
-32,000
-
-%
Nov 15, 2023
Beaird Harris Wealth Management, LLC
unchanged
-
-14.00
72.00
-%
Nov 15, 2023
MORGAN STANLEY
reduced
-1.24
-321,335
1,600,050
-%
Nov 14, 2023
Matrix Capital Management Company, LP
unchanged
-
-5,651,260
30,399,900
0.36%
Nov 14, 2023
TWO SIGMA INVESTMENTS, LP
reduced
-45.47
-55,053
46,858
-%
Nov 14, 2023
LAZARD ASSET MANAGEMENT LLC
added
4.44
-
3,000
-%
Nov 14, 2023
TANG CAPITAL MANAGEMENT LLC
added
5.72
-490,471
4,030,220
0.57%
Nov 14, 2023
MPM ASSET MANAGEMENT LLC
unchanged
-
-911,630
4,903,940
2.63%
Nov 14, 2023
CSS LLC/IL
unchanged
-
-13,151
70,748
-%

1–10 of 49

Latest Funds Activity

Are funds buying ADAP calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ADAP
No. of Funds

Schedule 13G FIlings of Adaptimmune Therapeutics Plc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Nov 08, 2023
long focus capital management, llc
2.9%
6,582,798
SC 13G
Jul 10, 2023
matrix capital management company, lp
17.29%
233,845,110
SC 13G/A
Mar 30, 2023
new enterprise associates 14, l.p.
10.3%
102,478,672
SC 13D/A
Feb 14, 2023
pfm health sciences, lp
3.0%
6
SC 13G/A
Feb 13, 2023
capital world investors
0.0%
0
SC 13G/A
Jan 18, 2023
baillie gifford & co
10.48%
103,019,634
SC 13G/A
Dec 02, 2022
baillie gifford & co
10.44%
102,618,552
SC 13G/A
May 09, 2022
pfm health sciences, lp
5.8%
6
SC 13G
Jan 18, 2022
baillie gifford & co
8.81%
82,538,112
SC 13G/A
Feb 16, 2021
baker bros. advisors lp
6.4%
58,985,262
SC 13G

Recent SEC filings of Adaptimmune Therapeutics Plc

View All Filings
Date Filed Form Type Document
Nov 14, 2023
8-K
Current Report
Nov 08, 2023
SC 13G
Major Ownership Report
Nov 08, 2023
8-K
Current Report
Nov 08, 2023
10-Q
Quarterly Report
Nov 03, 2023
8-K
Current Report
Nov 01, 2023
3
Insider Trading
Oct 31, 2023
8-K
Current Report
Sep 01, 2023
4
Insider Trading
Aug 31, 2023
8-K
Current Report

Peers (Alternatives to Adaptimmune Therapeutics Plc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
32.8B
-
14.55% 467931.97%
-3.8K
218.4K
- -102.45%
29.6B
10.7B
8.07% -55.95%
-8.54
2.78
-53.67% -129.46%
20.0B
1.7B
4.90% -25.16%
-39.17
11.59
79.37% 56.87%
16.7B
2.3B
9.83% -8.58%
113.5
7.22
15.05% 75.21%
11.8B
3.6B
0.63% -32.44%
27.88
3.28
8.35% -51.49%
MID-CAP
5.7B
272.9M
1.64% -5.18%
-9.43
20.95
141.38% 4.43%
5.2B
-
21.89% 247.20%
-8.88
48.33
54.84% -12.96%
3.6B
631.9M
1.65% 46.39%
-24.37
5.74
23.54% 31.53%
3.1B
223.4M
6.77% 16.65%
-15.53
14.03
- -26.24%
3.1B
256.2M
21.69% -2.64%
-16.98
12
2.51% -17.66%
SMALL-CAP
1.5B
348.4M
17.40% -16.91%
24.23
4.31
81.69% -7.29%
648.3M
1.0B
-14.02% -66.99%
-1.18
0.62
-43.15% 58.48%
108.4M
6.4M
10.81% -79.60%
-0.66
16.83
-44.11% 50.48%
18.7M
-
-19.00% 3569.57%
-0.39
-
- -13.74%
8.0M
-
- -82.21%
-0.12
-
- -29.23%

Adaptimmune Therapeutics Plc News

Latest updates
Stocks Register25 Nov 202306:02 pm2 days ago
StreetInsider.com08 Nov 202312:32 pm20 days ago
Nasdaq07 Nov 202308:00 am21 days ago
Yahoo Finance11 Sep 202307:00 am2 months ago
Yahoo Finance09 Aug 202307:00 am3 months ago
Yahoo Finance16 Jul 202307:00 am4 months ago
Yahoo Finance03 Jul 202307:00 am4 months ago
Nasdaq29 Jun 202307:00 am5 months ago
Yahoo Finance29 Jun 202307:00 am5 months ago
Yahoo Finance28 Jun 202307:00 am5 months ago
Yahoo Finance26 Jun 202307:00 am5 months ago

Financials for Adaptimmune Therapeutics Plc

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue42.7%7,319,0005,130,00047,601,00011,028,0007,007,0005,538,0003,575,0001,417,0001,203,0003,095,000434,0001,502,0001,193,000502,000761,000728,000237,000651,0001,065,0001,479,00040,792,000
Costs and Expenses7.8%53,952,00050,038,00045,945,00038,270,00049,997,00049,290,00053,556,00044,281,00043,384,00042,407,00038,323,00039,015,00037,068,00030,755,00030,525,00031,083,00040,358,00035,659,00033,792,00033,415,00033,774,000
  S&GA Expenses-19.5%16,164,00020,073,00020,397,00015,218,00016,815,00014,550,00016,804,00014,776,00015,173,00013,539,00013,817,00013,238,00013,001,00010,295,0009,261,00010,729,00010,741,00010,148,00011,773,00010,816,00010,290,000
  R&D Expenses26.1%37,788,00029,965,00025,548,00023,052,00033,182,00034,740,00036,752,00029,505,00028,211,00028,868,00024,506,00025,777,00024,067,00020,460,00021,264,00020,354,00029,617,00025,511,00022,019,00022,599,00023,484,000
EBITDA Margin100.0%--1.16-1.49-5.81-9.58-14.41-17.64-24.67-23.97-22.90-38.36-32.83-38.52-56.75-82.16-122-----
Income Taxes1.0%687,000680,000625,000994,000399,000470,000634,000209,000208,00076,000298,00052,00015,00025,00070,00088,00087,00065,0002,000135,000133,000
Earnings Before Taxes-116.9%-44,914,000-20,709,0001,661,000-28,256,000-41,022,000-44,050,000-49,631,000-38,649,000-42,193,000-38,992,000-37,465,000-36,561,000-35,417,000-29,855,000-28,097,000-29,276,000-39,215,000-41,022,000-27,410,000-35,868,0005,375,000
EBT Margin100.0%--1.25-1.57-6.00-9.88-14.87-18.24-25.58-24.90-23.85-38.36-32.83-38.52-56.75-82.16-122-----
Net Income-113.2%-45,601,000-21,389,0001,036,000-29,250,000-41,421,000-44,520,000-50,265,000-38,858,000-42,401,000-39,068,000-37,763,000-36,613,000-35,432,000-29,880,000-28,167,000-29,364,000-39,302,000-41,087,000-27,412,000-36,173,0005,242,000
Net Income Margin100.0%--1.29-1.60-6.09-9.98-15.00-18.36-25.71-25.00-23.92-38.47-32.87-38.58-56.87-82.34-122-----
Free Cashflow100.0%--44,978,000-39,632,000-1,373,000-58,166,000-50,211,000-61,515,000129,912,000-46,834,000-33,231,000-47,692,000-30,383,000-17,031,000-25,183,00016,665,000-12,688,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-13.5%297343288329332388420470354390412451479512285182208240270277310
  Current Assets-16.2%219262214255264321359415300337359398427458228120147175200231262
    Cash Equivalents20.9%93.0077.0012010879.0010091.0015245.0055.0037.0061.0083.0012791.0055.0044.0039.0054.0072.00157
  Net PPE-5.3%53.0055.0054.0054.0048.0045.0037.0030.0029.0029.0028.0028.0027.0027.0029.0031.0032.0034.0036.0036.0038.00
Liabilities-3.6%20921620424721924625726411311210211010310599.0058.0061.0053.0051.0030.0033.00
  Current Liabilities-1.3%75.0076.0064.0065.0066.0074.0066.0063.0041.0041.0031.0039.0035.0039.0030.0034.0037.0028.0023.0024.0030.00
Shareholder's Equity-30.4%88.0012784.0082.00113142163206241278309341376408186124148187220247276
  Retained Earnings-4.9%-975-929-908-909-880-838-794-743-704-662-623-585-549-513-483-455-426-387-345-318-282
  Additional Paid-In Capital0.4%1,0611,058993991985980965960955950942936933929678586583581578574570
Accumulated Depreciation4.7%43.0041.0039.0039.0035.0036.0037.0036.0035.0034.0033.0031.0029.0026.0024.0024.0021.0020.0018.0016.00-
Shares Outstanding0.7%1,3621,352994987983963940929937934931929928781740631629629628584582
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-3.2%-45,159-43,762-37,2832,042-48,159-41,251-54,401133,928-45,200-31,459-46,540-29,216-16,317-24,91516,857-12,528-29,608-34,168-36,203-31,6859,939
  Share Based Compensation-17.1%3,1793,8371,6763,9463,6635,0455,5864,8275,0195,4495,3343,0623,2802,6241,4482,5581,8203,1963,4793,7494,042
Cashflow From Investing2027.2%57,3062,69448,34120,95228,85144,109-4,775-28,49134,85147,67821,7627,608-27,580-187,005-71,94723,68335,04518,56117,656-52,411942
Cashflow From Financing4157.1%59614.001961,4031,4529,97735.0052.001392,563534122466248,01991,444--33036.00104100,162

ADAP Income Statement

2023-09-30
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS    
Revenue$ 7,319,000$ 7,007,000$ 60,050,000$ 16,120,000
Operating expenses    
Research and development(37,788,000)(33,182,000)(93,301,000)(104,674,000)
General and administrative(16,164,000)(16,815,000)(56,634,000)(48,169,000)
Total operating expenses(53,952,000)(49,997,000)(149,935,000)(152,843,000)
Operating loss(46,633,000)(42,990,000)(89,885,000)(136,723,000)
Interest income2,149,000324,0004,368,0001,019,000
Gain on bargain purchase  22,049,000 
Remeasurement on bargain purchase(106,000)   
Other income (expense), net(324,000)1,644,000(494,000)1,001,000
Loss before income tax expense(44,914,000)(41,022,000)(63,962,000)(134,703,000)
Income tax expense(687,000)(399,000)(1,992,000)(1,503,000)
Net loss attributable to ordinary shareholders$ (45,601,000)$ (41,421,000)$ (65,954,000)$ (136,206,000)
Net loss per ordinary share    
Basic (in dollars per share)$ (0.03)$ (0.04)$ (0.06)$ (0.14)
Diluted (in dollars per share)$ (0.03)$ (0.04)$ (0.06)$ (0.14)
Weighted average shares outstanding:    
Basic (in shares)1,357,849,656980,791,1141,153,791,567961,354,122
Diluted (in shares)1,357,849,656980,791,1141,153,791,567961,354,122

ADAP Balance Sheet

2023-09-30
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 90,059,000$ 108,033,000
Marketable securities - available-for-sale debt securities71,669,00096,572,000
Accounts receivable, net of allowance for expected credit losses of $0 and $0789,0007,435,000
Other current assets and prepaid expenses56,851,00043,330,000
Total current assets219,368,000255,370,000
Restricted cash3,013,0001,569,000
Operating lease right-of-use assets, net of accumulated amortization of $11,930 and $9,47021,302,00018,019,000
Property, plant and equipment, net of accumulated depreciation of $42,543 and $38,58852,571,00053,516,000
Intangible assets, net of accumulated amortization of $5,008 and $4,676384,000442,000
Total assets296,638,000328,916,000
Current liabilities  
Accounts payable13,922,0004,753,000
Operating lease liabilities, current5,081,0002,728,000
Accrued expenses and other current liabilities26,831,00031,215,000
Restructuring provision 2,285,000
Deferred revenue, current29,312,00023,520,000
Total current liabilities75,146,00064,501,000
Operating lease liabilities, non-current20,520,00020,349,000
Deferred revenue, non-current111,487,000160,892,000
Other liabilities, non-current1,356,0001,296,000
Total liabilities208,509,000247,038,000
Stockholders' equity  
Common stock - Ordinary shares par value £0.001, 1,702,760,280 authorized and 1,361,595,036 issued and outstanding (2022: 1,282,773,750 authorized and 987,109,890 issued and outstanding)1,863,0001,399,000
Additional paid in capital1,061,420,000990,656,000
Accumulated other comprehensive gain/(loss)102,000(875,000)
Accumulated deficit(975,256,000)(909,302,000)
Total stockholders' equity88,129,00081,878,000
Total liabilities and stockholders' equity$ 296,638,000$ 328,916,000
ADAP
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
 CEO
 WEBSITEwww.adaptimmune.com
 EMPLOYEES534

Adaptimmune Therapeutics Plc Frequently Asked Questions


What is the ticker symbol for Adaptimmune Therapeutics Plc?

Ticker symbol for Adaptimmune Therapeutics Plc is ADAP.

What is the market capital of Adaptimmune Therapeutics Plc (ADAP)?

As of Mon Nov 27 2023, market cap of Adaptimmune Therapeutics Plc is 653.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADAP stock?

You can check ADAP's fair value in chart. The fair value of Adaptimmune Therapeutics Plc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adaptimmune Therapeutics Plc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADAP so that you know how good or bad the model has been in the past so you can discard it if needed.

Is Adaptimmune Therapeutics Plc stock overpriced or underpriced?

The fair value guage provides a quick view whether ADAP is over valued or under valued. Whether Adaptimmune Therapeutics Plc is cheap or expensive depends on the assumptions which impact Adaptimmune Therapeutics Plc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADAP.

What is Adaptimmune Therapeutics Plc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Nov 27 2023, ADAP's PE ratio (Price to Earnings) is -6.86 and Price to Sales (PS) ratio is 9.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADAP PE ratio will change depending on the future growth rate expectations of investors.